• Explore /
  • Poster
  • / Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

Abstract Poster

Authors

null

Connie Lee Batlevi

Memorial Sloan Kettering Cancer Center, New York, NY

Connie Lee Batlevi , Stephanie De Frank , Caitlin Stewart , Paul A. Hamlin , Matthew J. Matasar , John F. Gerecitano , Alison J. Moskowitz , Audrey M. Hamilton , Andrew David Zelenetz , Pamela Drullinsky , David J. Straus , Anita Kumar , Craig H. Moskowitz , Joanna Dicostanzo , Devin Callan , Dana Tsui , Jurgen Rademaker , Heiko Schöder , Ai Ni , Anas Younes

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02756247

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7520)

DOI

10.1200/JCO.2018.36.15_suppl.7520

Abstract #

7520

Poster Bd #

157

Abstract Disclosures

Similar Posters

First Author: Matthew Steven Davids

First Author: Ki Hyun Kim

First Author: Loretta J. Nastoupil

First Author: Thomas E. Witzig